Cerebid Technologies - PA Philadelphia, Philadelphia 19104

Cerebid Technologies entered the industry of Commercial Medical Research in 2011 and has grown to employ 1 to 4 people, generating an annual revenue of $100.000 to $499.999. The NAICS classifies this business under the code 541712, which describes it as a Commercial Medical Research. For further clarification, the SIC classifies this business under the code 8731 and described it as a Commercial Medical Research. The business provides service to the B2B market.

To acquire more information, please contact Douglas Smith by calling (215) 898-0881 during business hours. You can also write to the business’ Single Location at 3160 Chestnut St # 200, Philadelphia, Pennsylvania PA 19104. You can also visit the company’s website at . View this business’ social media profiles on Twitter or on Facebbok .

Company: Cerebid Technologies
Representative: Douglas Smith
Place of Business: 3160 Chestnut St # 200, Philadelphia, PA 19104
Contact Number: (215) 898-0881
Type of Service: Commercial Medical Research
SIC Number: 8731
NAICS Number: 541712
Locality: Single Location
Market Type: B2B (Business to Business)
Began: 2011
Income/Year: $100.000 to $499.999
Laborers: 1 to 4
Share This Company:

Cerebid Technologies is a company operating from Philadelphia, Pennsylvania providing professional Commercial Medical Research and relevant B2B variables. It was founded in 2011 and registered with the SIC code 8731 as Commercial Medical Research, and with the NAICS code 541712 as Commercial Medical Research.

With a current employee count of 1 to 4, Cerebid Technologies has gone to report making $100.000 to $499.999 per annum on its journey towards growth. This company invites you to contact its representative Douglas Smith at (215) 898-0881 for related queries, or to locate its Single Location using the coordinates 39.953553,-75.18659.

The Single Location can also be found at the street address 3160 Chestnut St # 200 in Philadelphia, Pennsylvania 19104 and can be engaged online through the company website at , the company Twitter , and Facebook page .